Indian Journal of Psychological Medicine
  Home | About Us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Contact | Advertise | Submission | Login 
Users Online: 346 
Wide layoutNarrow layoutFull screen layoutHome Print this page Email this page Small font sizeDefault font sizeIncrease font size

 Table of Contents    
Year : 2018  |  Volume : 40  |  Issue : 4  |  Page : 370-371  

Alopecia associated with use of methylphenidate: A case series

Children and Young People Services, Northumberland, Tyne and Wear NHS Foundation Trust, Morpeth, UK

Date of Web Publication16-Jul-2018

Correspondence Address:
Dr. Sundar Gnanavel
Northumberland, Tyne and Wear NHS Foundation Trust, Morpeth
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/IJPSYM.IJPSYM_63_18

Rights and Permissions

In this case series, we report three cases of alopecia associated with use of methylphenidate for ADHD (Attention deficit hyperactivity disorder), that reversed with discontinuation of methylphenidate.

Keywords: ADHD, alopecia, methylphenidate

How to cite this article:
Gnanavel S, Hussain S. Alopecia associated with use of methylphenidate: A case series. Indian J Psychol Med 2018;40:370-1

How to cite this URL:
Gnanavel S, Hussain S. Alopecia associated with use of methylphenidate: A case series. Indian J Psychol Med [serial online] 2018 [cited 2020 Jun 5];40:370-1. Available from:

Methylphenidate is a stimulant drug considered the first-choice medication for attention-deficit hyperactivity disorder (ADHD). Although drug-induced alopecia is a common adverse effect with a variety of medications, alopecia with methylphenidate is a rarely reported side effect. In this case series, we present three children and adolescents with ADHD who developed severe alopecia with methylphenidate and improved with discontinuation of the same.

   Case Reports Top

Case 1

Mstr LB is a 9-year-old boy diagnosed with ADHD based on poor attention span, forgetfulness, fidgetiness, restlessness, and reckless behavior in multiple settings including school and home. He was started on immediate-release methylphenidate 5 mg/day which was slowly titrated upward. After about a week of increase in the dose of methylphenidate to 30 mg/day, both the child and his parents noticed some hair loss initially in the temporal region. The hair loss progressed rapidly in the next 2–3 weeks, with patches of lost hair in temporal and parietal scalp regions, with the scalp clearly visible in these areas. The medication was stopped, and he was started on lisdexamfetamine. Within 3–4 weeks of stopping methylphenidate, regrowth of hair follicles was noted, and he regained his hair in around 3 months.

Case 2

Ms NT is a 13-year-old girl who presented to our clinic with a poor concentration in school lessons and being bouncy, always “on the go,” impatient, and impulsive in different settings as described by her parents. She was diagnosed with ADHD and started on longer-acting preparation of methylphenidate (Concerta XL) 18 mg which was subsequently increased to 27 mg once daily. Subsequently, within a week, she noted diffuse hair loss and thinning of hair which progressively worsened (with an obvious decrease in hair thickness as commented by her friends and family). Discontinuation of methylphenidate and switch to atomoxetine resulted in gradual regrowth of hair over the next 3 months.

Case 3

Mstr WG is a 12-year-old boy who presented to our clinic with risky behaviors, including running across roads unsupervised, highly distracted during school lessons, poorly organized, hyperactive, and finding it difficult to remain still. He was diagnosed with ADHD and started on immediate-release methylphenidate 5 mg/day. The dose was gradually increased to 20 mg/day. He responded well to the medication. However, within a fortnight of increasing the dose to 20 mg, his parents started to notice patchy hair loss in the frontal and parietal region (with scalp being visible in these areas clearly). Discontinuation of methylphenidate and switch to atomoxetine resulted in gradual regrowth of hair over the next 6 months.

There were no losses in the eyebrows, eyelashes, or elsewhere in any of these cases. They were not taking any other medication for ADHD or otherwise. There was no personal or family history of hair loss. Trichotillomania with medication for ADHD has been reported, and this was explored as a possibility.[1] No pulling of hair suggestive of trichotillomania was reported by patients and corroborated by parents. The patients were investigated for common physical causes of hair loss, including complete blood counts, biochemical analysis, folic acid, vitamin B12, thyroid function tests, and serum iron. All the investigations were normal. In all these cases, there was a clear temporal association between onset of hair loss and increase in dose of methylphenidate as well stopping medication and reversal of hair loss. Opinion from physician suggested, drug-induced hair loss as the possible explanation since other possibilities were ruled out by investigations. According to Naranjo's algorithm, the drug-related adverse effect can be classified as “probable” adverse drug reaction (score-6).[2]

To the best of our knowledge, there is only one previous case report of alopecia with methylphenidate.[3] Atomoxetine, the second-line choice for ADHD, has been implicated in alopecia as well.[4] This has definite implications on compliance to medication as hair loss can be associated with psychological distress and effect on mental health particularly in adolescents. While the exact pathophysiological mechanism behind this remains unknown, the possibility of a direct toxic effect on the hair follicles remains a possibility.[5] Research into the precise mechanism of hair loss due to methylphenidate and ascertaining if this is a dose-related or a nondose-related side effect is essential to shed more light. In addition, exploring any patient or environmental characteristics that make a patient more vulnerable to methylphenidate-induced alopecia might be helpful in planning further management.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Akaltun İ, Kara T. Atomoxetine-related trichotillomania in a boy with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2017;27:923.  Back to cited text no. 1
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  Back to cited text no. 2
Sayin A, Turkoglu S. Methylphenidate-related severe and diffuse hair loss: A case report. Klin Psychopharmacol B 2016;26:327.  Back to cited text no. 3
Ceylan U, Yalcin O. Atomoxetine related hair loss in a teenager: A case report. Bull Clin Psychopharmacol 2010;20:258-60.  Back to cited text no. 4
Piraccini BM, Iorizzo M, Rech G, Tosti A. Drug-induced hair disorders. Curr Drug Saf 2006;1:301-5.  Back to cited text no. 5


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Case Reports

 Article Access Statistics
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal